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Aim: To compare the molecule levels of plasma miRNA (miR-22, miR-24, miR-92b,
miR-320a and miR-423-5p) in acute decompensated heart failure (ADHF) patients
before and after treatment with the controls who do not have HF.
Method: This study included 47 (mean age: 61.7011.75, 63.8% men) patients
hospitalized in intensive care unit with the diagnosis of ADHF and 30 (mean age:
57.138.32, 46.66% men) healthy population. Peripheric blood was withdrawn from
the patients at admission and after treatment and the miR-22, miR-24, miR-92b, miR
320a and miR-423-5p levels were compared with the control group. Venous blood
was withdrawn from patients two times, ﬁrst at hospitalization and second after
treatment before discharge and only once from the controls and were kept at -80
Celsius. After sample collection was concluded, the levels of miRNA detected from
peripheral blood cells (leukocytes) were calculated using the method PCR, and
comparison between groups and within the group of HF miRNA differences were
expressed as fold change (2 to the power of -DD Ct value was used).
Results: The demographic features and the treatment being received at admission is
listed in Table-1. All patients received parenteral furosemide and 8.5% of them had
inotropic drugs at admission. The basal (decompansated) miR-22 levels were detected
as 2.33 fold lower in the patient group than the control group. After medical treatment
before discharge (compensated) the decrease was 1,23 folds, resulting in closer levels
to the control group. Similar level difference was detected with the miRNA 24. The
miR-92 levels were increased both at admission and at discharge compared with the
controls. The amount of increase was 2.33 fold at admission and 3 folds at discharge.
The differences of the levels of miR-423-5p and 320a were not signiﬁcant (Table-2).
The difference of the miRNA levels were similar between ischemic and non-ischemic
heart failure groups.
Conclusion: 1) Acute decompansated heart failure patients have signiﬁcantly
decreased (>2-fold) miR-22 and 24 levels, after obtaining compensation with medical
treatment, it gets closer to the normal population with treatment. 2) In this group of
patients miRNA-22 and 24 levels can be a useful indicator (biomarker) for the
effectiveness of drug therapy.Table-1. General characteristics of HF and control groups
HF group
(n ¼ 47)
Control group
(n ¼ 30) p value
Age (mean)
Gender (m/f)
BMI
HT
HLP
DM
Drugs
BB
ACEi
MRA
61.70
30 / 17
28.07
21 (%44.7)
35 (%74.5)
29 (%61.7)
39 (%88.6)
26 (%59.1)
13 (%27.6)
57.13
14 / 16
27.16
17 (56.7)
18 (%60)
12 (%40)
4 (%13.3)
8 (%26.7)
0 (%0)
0.025
0.013
0.137
0.214
0.139
0.534
<0.001
<0.001
<0.001
HF: heart failure, BMI: body mass index, HT: hypertension, HLP: hyperlipidemia, DM: diabetes
mellitus BB: beta blocker, ACEi: angiotensin converting enzyme inhibitors, MRA: miner-
alokortikoid antogonists
Table-2. miRNA expression fold changes
According to
the normal at admission
According to
the normal at discharge
miR- 22
miR- 24
miR- 92b
miR- 320a
miR- 423-5p
- 2.39 f
- 2.07 f
+ 2.33 f
- 1.56 f
- 1.16 f
- 1.23 f
- 1.59 f
+ 3.0 f
- 1.46 f
+ 1.3 f
miRNA (miR): mikroribonükleic acid
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Background and Aim: Percutaneous coronary intervention (PCI) does not often have
optimal results despite restoration of coronary blood ﬂow at myocardial recovery
because of impaired microvascular perfusion. Previous studies have focused on the
starting time and dosage of tiroﬁban. This study aimed to investigate and evaluate with
99mTc-sestamibi scan whether the results of PCI can be changed by maintenance
infusion of the tiroﬁban for 24 or 48 hours in patients presenting with anterior STEMI.
Methods: The study consisted of 84 patients with anterior STEMI who were candi-
dates to undergo primary PCI and whose occlusion were in proximal or mid left
anterior descending artery (LAD), were given 25mg/kg/3 minutes tiroﬁban and
randomized maintenance infusion of 0.15mg/kg/minute for 24 or 48 hours. A resting
99mTc sestamibi scan was performed at post-procedure 5th day before discharge and
the primary efﬁcacy end point was a 5-point scoring system for perfusion defect
severity. Major adverse cardiac events were deﬁned as death from any cause, rein-
farction, and clinically driven target-vessel revascularization within the ﬁrst 6 months.
Results: The baseline characteristics were similar at 24 (n¼42) and 48 hours (n¼42)
infusion groups. There was no signiﬁcant difference at the anticipated symptom onset
to presentation time (3.832.09 h at 24 hour infusion group and 4.102.01 h at 48
hour infusion group, p¼0.380) and door to balloon time (45.7115.91 min. at 24 hour
infusion group and 48.9520.78 min. at 48 hour infusion group, p¼0.542) between
two groups. Except for basal anteroseptal and basal anterior segments, signiﬁcant
differences were obtained from the reduction of 5-point scoring system for perfusion
defect severity in segments and in the summed rest scores (apex 2.900.95,
2.041.43; p<0.05; mid-anterior 1.880.94, 1.281.13; p<0.05; mid-anteroseptal
2.280.83, 1.731.14; p<0.05; apical anterior 2.690.81, 2.001.43; p<0.05;,
apical septal 2.640.87, 1.951.32; p<0.05;, apical lateral 2.500.94, 2.211.27;
p<0.05, basal anterior 0.110.32, 0.330.75; p¼0.09; basal anteroseptal 0.660.72,
0.500.91; p¼0.288, SRS 15.614.60, 11.977.34; p<0.05). No signiﬁcant effect
was observed on major adverse cardiac events at 6 months. The safety proﬁle did not
differ between 24 and 48 hour infusion of tiroﬁban.
Conclusion: The use of tiroﬁban, when administered at a high dose of bolus and
maintained for 48 hours, is safe and signiﬁcantly reduces perfusion defect severity in
patients with anterior STEMI presenting early after symptom onset and undergoing
primary PCI.LS C19
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Table 1
24 hour
tiroﬁban
maintenance
48 hour
tiroﬁban
maintenance p Value
Age 59.0710.69 57.6714.30 0.254
Male Sex 37 (88%) 34 (80%) 0.612
Diabetes Mellitus 7 (16%) 5 (12%) 0.764
Hypertension 15 (35%) 12 (29%) 0.712
Smoking 23 (54%) 24 (57%) 0.762
Symptom onset
to hospital
arrival (hour)
3.832.09 4.102.01 0.380
Door to balloon time
(minute)
45.7115.91 50.9535.78 0.542
Reference Vessel
Diameter
3.270.34 3.460.38 0.201
5 point scoring system
for perfusion
defect severity
Apex 2.900.95 2.041.43 <0.05
Apical septal 2.650.87 1.951.32 <0.05
Mid-anteroseptal 2.280.83 1.731.14 <0.05
Basal-anteroseptal 0.660.72 0.50.92 0.357
Mid-anterior 1.880.94 1.281.13 <0.05
Basal-anterior 0.110.32 0.330.75 0.095
Apical-anterior 2.690.81 2.01.43 <0.05
Apical-lateral 2.500.94 2.211.27 <0.05
Summed Rest Score 15.614.60 11.977.34 <0.05
Baseline characteristics and 5 point scoring system for perfusion defect severity results of
anterior STEMI patients
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SYNTAX Score is a Predictor of Angiographic No-Reﬂow in Patients with ST
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Objectives: The no-reﬂow phenomenon has a negative prognostic value in patients
with acute ST elevation myocardial infarction (STEMI). SYNTAX score (SS) quan-
tiﬁes extent and complexity of angiographic disease and predict long-term mortality
and morbidity in STEMI. We aimed to assess the no-reﬂow and its possible rela-
tionships with SS and clinical characteristics in patients with STEMI treated with
primary percutaneous coronary intervention (PPCI).
Methods: In this study, 880 STEMI patients with STEMI treated with PPCI were
prospectively included (646 male, 234 female; mean age 58.512.4 years). The SS,
Thrombolysis in Myocardial Infarction (TIMI) ﬂow grade score and TIMI myocardial
blush grade (MBG) score were determined in all patients. No-reﬂow was deﬁned as
TIMI grade 0, 1 and 2 ﬂows or TIMI grade 3 with MBG 0 and 1. The patients were
divided into two groups as normal ﬂow group and no-reﬂow group.
Results: No-reﬂow was observed at 32.8% of patients. The mean SS of no-reﬂow
group was higher than normal ﬂow group (19.26.8/12.96.1, p<0.001). On
multivariate logistic regression analysis, SS (b¼0.872, %CI¼0.845-0.899, p<0.001),
diabetes (b¼0.767, %CI¼0.128-4.597, p¼0.004), anterior myocardial infarction
(b¼5.421, %CI¼1.369-21.469, p¼0.025) and thrombus grade after wiring (b¼2.537,
%CI¼1.506-4.273, p<0.001) were independent predictors of no-reﬂow. The cutoff
value of SS obtained by the ROC curve analysis was 19.75 for the prediction of
no-reﬂow (sensitivity: 70.6%, speciﬁcity: 69.4%).
Conclusion: TheSS is a predictor of no-reﬂow in patientswith STEMI treatedwith PPCI.Comparison of baseline demographic, echocardiographic and angiographic
characteristics
Variables
Normal ﬂow
(n¼591)
No-reﬂow
(n¼289) p value
SYNTAX Score 12.96.1 19.26.8 <0.001
Age, years 56.312.2 61.811.7 < 0.001
Ejection fraction (%) 46.79.5 43.19.1 <0.001
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Objectives: The aim of this study was to evaluate the prognostic value of D-dimer in
patients with STEMI undergoing primary percutaneous coronary intervention (PCI).
Background: The prognostic value of D-dimer has been documented in patients with
acute coronary syndrome without ST-segment elevation. However, its value in acute
ST-segment elevation myocardial infarction (STEMI) remains unclear.
Methods: We prospectively enrolled 453 consecutive STEMI patients (mean age
55.612.4 years, 364 male, 89 female) undergoing primary PCI. The study population
was divided into tertiles based on admission D-dimer values. The high D-dimer group
(n¼151) was deﬁned as a value in the third tertile (>0.72 ug/ml FEU), and the low
D-dimer group (n¼302) included those patients with a value in the lower two tertiles
(0.72 ug/ml FEU). Clinical characteristics, in-hospital and six-month outcomes of
primary PCI were analyzed.
Results: The patients of the high D-dimer group were older (mean age 60.113.5 vs.
52.410.6, p<0.001).Higher in-hospital cardiovascularmortality and six-month all-cause
mortality rates were observed in the high D-dimer group (7.2% vs. 0.6%, p<0.001 and
13.9% vs. 2%, p<0.001, respectively). In Cox multivariate analysis; a high admission
D-dimer value (>0.72ug/mlFEU)was found tobe a powerful independent predictor of six-
month all-causemortality (odds ratio: 10.1, 95% conﬁdence interval: 1.24-42.73, p¼0.03).
Conclusions: These results suggest that a high admission D-dimer level was asso-
ciated with increased in-hospital cardiovascular mortality and six-month all-cause
mortality in patients with STEMI undergoing primary PCI.
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Background: Fragmented QRS complex (fQRS) is associated with worse outcomes
in several cardiovascular conditions. However, alterations in fQRS in patients with ST
elevation myocardial infarction (STEMI) who underwent primary percutaneous
coronary intervention (PCI) and association of fQRS with myocardial blush grade
(MBG) has not been investigated until now. In this study, we aimed to investigate the
association of MBG after primary PCI with evolution of fQRS.
Methods: Our study consisted of 401 consecutive patients with STEMI who under-
went primary PCI. Patients were categorized into two subgroups according to
persistence or new-onset of fQRS (Group 1) and absence or resolution of fQRS
(Group 2) at 48 hours after primary PCI. The evolution of fQRS on pre and post-PCI
ECG and their relation with myocardial reperfusion parameters were investigated.
Results: Patients in group 1 showed older age, higher rate of smoking, lower HDL-
cholesterol, lowerLVEF, increasedadmission time, higherTIMI framecount andhigh rateof
patients withMBG<3 compared to patients with group 2 (p<0.05). In correlation analysis,
LVEF showed positive correlation withMBG (r¼0.448, p<0.001) and negative correlation
with the number of leads with fQRS (r¼-0.335, p<0.001). In multivariate regression anal-
ysis, new-onset or persistence of fQRS after primary PCI is signiﬁcantly associated with
MBG<3, peak CK-MB level, pre-PCI fQRS at anterior localization and smoking.
Conclusion: In conclusion, despite completeSTsegment resolution in all patients, fQRS is
independently associated with impairedmicrovascular myocardial perfusion. So, fQRS, as
a simple and easily available non-invasive marker, may be useful in stratiﬁcation of high-
risk patients with increased extent of infarcted myocardium who underwent primary PCI.
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Previous studies showed that serum total bilirubin (TB) concentration was inversely
related with stable coronary artery disease (CAD), diabetes mellitus (DM),ol 62/18/Suppl C j October 26–29, 2013 j TSC Abstracts/ORALS
